Physician profile
Brian R Cain
NPI 1417951039
$19,500.70
in general payments reported to CMS, 2019-2025
54 companies · $2,881 in 2025
The $2,881 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,729 · 2020: $2,566 · 2021: $2,748 · 2022: $2,508 · 2023: $2,740 · 2024: $3,328 · 2025: $2,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,934 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,933.81 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,991.18 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,914.06 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $1,868.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,755.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,693.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,269.91 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Glaxosmithkline, LLC. | $875.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $714.88 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $694.62 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $601.12 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $520.92 | 2019-2022 | |
| Abbott Laboratories | $492.86 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $400.28 | 2019-2020 | |
| Evoke Pharma, INC. | $398.53 | 2021-2025 | Gimoti |
| Bayer Healthcare Pharmaceuticals INC. | $375.37 | 2021-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.